State Street SPDR S&P Pharmaceuticals ETF
XPH
75 hedge funds and large institutions have $182M invested in State Street SPDR S&P Pharmaceuticals ETF in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 28 reducing their positions, and 21 closing their positions.
41% more capital invested
Capital invested by funds: $129M → $182M (+$53.1M)
17.13% more ownership
Funds ownership: 34.11% → 51.24% (+17%)
12% less funds holding
Funds holding: 85 → 75 (-10)
32% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 28
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $234K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$26.1M |
| 2 |
BB
Bell Bank
Fargo,
North Dakota
|
+$18.9M |
| 3 |
Morgan Stanley
New York
|
+$10.9M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$8.72M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$4.12M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.35M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.25M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.04M |
| 5 |
OLA
Oliver Luxxe Assets
Gladstone,
New Jersey
|
-$1.04M |
XPH Hedge Fund Activity: Q1 2018 in Review
75 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2018, worth a combined $182M — up 41% from $129M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of XPH and 12 opened new positions — a net loss of 9 holders — while 28 trimmed existing stakes and 19 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $26.1M. The largest seller was Psagot Value Holdings, cutting an estimated $4.12M.
- 75 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2018, down from 85 in Q4 2017.
- Funds reported $182M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2018, up 41% quarter-over-quarter.
- 12 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2018 and 21 closed out, a net change of -9 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2018 was Deutsche Bank, an estimated $26.1M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2018 was Psagot Value Holdings, an estimated $4.12M sold.
Based on aggregated 13F filings for Q1 2018.